Geode Capital Management LLC Acquires 52,506 Shares of CVS Health Corporation $CVS

Key Points

• Geode Capital Management increased its CVS Health stake by 52,506 shares in the fourth quarter, bringing its total holding to 29.0 million shares worth about $2.29 billion. Institutional investors continue to own the vast majority of the stock.
• CVS reported strong quarterly results, with revenue of $100.43 billion and EPS of $2.57, both ahead of analyst expectations. The company also raised its full-year 2026 EPS guidance to $7.30-$7.50.
• Recent business developments include CVS Caremark restoring coverage of Zepbound and adding Eli Lilly’s new obesity pill to standard drug plans, while CVS Health Ventures led a $40 million investment in health-tech firm H1. These moves highlight CVS’s focus on expanding care access and digital growth.

Geode Capital Management LLC grew its holdings in shares of CVS Health Corporation (NYSE:CVS - Free Report) by 0.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 29,040,271 shares of the pharmacy operator's stock after buying an additional 52,506 shares during the quarter. Geode Capital Management LLC owned approximately 2.29% of CVS Health worth $2,294,689,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in CVS. Sei Investments Co. lifted its position in CVS Health by 17.4% during the 2nd quarter. Sei Investments Co. now owns 905,715 shares of the pharmacy operator's stock worth $62,474,000 after buying an additional 134,535 shares in the last quarter. The Manufacturers Life Insurance Company raised its holdings in shares of CVS Health by 1.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 1,121,377 shares of the pharmacy operator's stock valued at $77,353,000 after purchasing an additional 13,329 shares during the period. Treasurer of the State of North Carolina raised its holdings in shares of CVS Health by 1.3% in the 2nd quarter. Treasurer of the State of North Carolina now owns 585,073 shares of the pharmacy operator's stock valued at $40,358,000 after purchasing an additional 7,588 shares during the period. HUB Investment Partners LLC raised its holdings in shares of CVS Health by 25.0% in the 2nd quarter. HUB Investment Partners LLC now owns 15,063 shares of the pharmacy operator's stock valued at $1,039,000 after purchasing an additional 3,011 shares during the period. Finally, Alliancebernstein L.P. raised its holdings in shares of CVS Health by 8.0% in the 2nd quarter. Alliancebernstein L.P. now owns 1,609,404 shares of the pharmacy operator's stock valued at $111,017,000 after purchasing an additional 119,439 shares during the period. 80.66% of the stock is owned by institutional investors.

Key Stories Impacting CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS Caremark said it will restore coverage of Eli Lilly’s weight-loss drug Zepbound and add Lilly’s new obesity pill to its standard drug plans, a move that could improve member access and make CVS’s drug formularies more competitive. Article Title
• Positive Sentiment: CVS Health Ventures led a $40 million investment in H1, reinforcing CVS’s push into health-tech and AI-driven provider data accuracy, which could support long-term digital growth initiatives. Article Title
• Positive Sentiment: Aetna launched “Aetna Mental Health On Demand,” giving members faster access to mental-health care and adding another visible example of CVS expanding its integrated care offerings. Article Title
• Positive Sentiment: CVS also expanded its Salesforce partnership to improve call-center service with AI tools, which may lower friction for members and providers and improve operating efficiency. Article Title
• Neutral Sentiment: Several reports focused on CVS’s dividend safety, with commentary suggesting the payout remains covered by cash flow; this is reassuring for income investors, but it is not a direct catalyst. Article Title
• Negative Sentiment: CVS filed suit to challenge Tennessee’s new PBM-pharmacy breakup law, signaling regulatory and legal pressure on part of its business model; however, this is more of a risk factor than an immediate earnings driver. Article Title

Insider Transactions at CVS Health

In other CVS Health news, EVP Tilak Mandadi sold 69,551 shares of the stock in a transaction that occurred on Friday, May 8th. The shares were sold at an average price of $89.58, for a total transaction of $6,230,378.58. Following the transaction, the executive vice president owned 10,133 shares in the company, valued at $907,714.14. This represents a 87.28% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Larry Robbins sold 1,983,538 shares of the stock in a transaction that occurred on Tuesday, May 19th. The stock was sold at an average price of $94.45, for a total transaction of $187,345,164.10. Following the transaction, the director owned 6,213,261 shares in the company, valued at approximately $586,842,501.45. The trade was a 24.20% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 3,441,551 shares of company stock worth $323,703,977. 0.85% of the stock is owned by company insiders.

CVS Health Stock Up 1.0%

Shares of CVS opened at $92.95 on Friday. CVS Health Corporation has a 52 week low of $58.50 and a 52 week high of $98.43. The firm has a market cap of $118.59 billion, a P/E ratio of 40.95, a price-to-earnings-growth ratio of 0.90 and a beta of 0.60. The firm's 50-day simple moving average is $81.71 and its 200 day simple moving average is $79.47. The company has a debt-to-equity ratio of 0.78, a quick ratio of 0.66 and a current ratio of 0.87.

CVS Health (NYSE:CVS - Get Free Report) last announced its quarterly earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 EPS for the quarter, beating analysts' consensus estimates of $2.21 by $0.36. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. The business had revenue of $100.43 billion for the quarter, compared to analyst estimates of $94.99 billion. During the same quarter in the prior year, the business earned $2.25 EPS. CVS Health's quarterly revenue was up 6.2% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. On average, analysts forecast that CVS Health Corporation will post 7.44 earnings per share for the current year.

CVS Health Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, May 4th. Investors of record on Thursday, April 23rd were paid a $0.665 dividend. The ex-dividend date was Thursday, April 23rd. This represents a $2.66 dividend on an annualized basis and a yield of 2.9%. CVS Health's dividend payout ratio is 117.18%.

Analyst Ratings Changes

CVS has been the topic of a number of research analyst reports. DA Davidson upped their target price on shares of CVS Health from $80.00 to $100.00 and gave the company a "buy" rating in a report on Thursday, May 7th. Barclays upped their target price on shares of CVS Health from $101.00 to $106.00 and gave the company an "overweight" rating in a report on Tuesday. Morgan Stanley upped their target price on shares of CVS Health from $93.00 to $106.00 and gave the company an "overweight" rating in a report on Thursday, May 14th. JPMorgan Chase & Co. upped their target price on shares of CVS Health from $101.00 to $111.00 and gave the company an "overweight" rating in a report on Tuesday, May 12th. Finally, Piper Sandler dropped their target price on shares of CVS Health from $101.00 to $99.00 and set an "overweight" rating on the stock in a report on Tuesday, March 31st. Twenty-two equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $98.88.

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.